Sep 2026· International Journal of Molecular Sciences· Vol 27· 0 citations· 37 references
Medicine
TL;DR
It is argued that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.
Abstract
Artificial intelligence (AI) is reshaping molecular oncology by making complex biological data tractable and by extending the reach of precision drug discovery. Its emerging value is particularly evident at the interface of immunoengineering and targeted therapy, where computational models can help prioritize tumor-selective antigens, predict neoantigen immunogenicity, optimize engineered receptors, support antibody and antibody–drug conjugate design, guide small-molecule discovery, refine genome-editing strategies, and anticipate treatment response. Across these applications, the central promise is not automation for its own sake, but a wider therapeutic window in which tumor control is increased while off-target toxicity is reduced. Yet the translational gap remains substantial. Many models are still preclinical, external validation is limited, and clinical implementation remains uncommon. This Commentary follows representative methods across a therapeutic continuum that now extends from target discovery and therapeutic engineering to imaging, liquid biopsy, resistance forecasting, combination selection, and drug repurposing. We argue that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.
This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.
D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al.· Current pharmaceutical desig...· 0 citations
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.
This review discusses AI‐guided strategies for material design, targeting, payload optimization, and in vivo delivery, with particular attention to protein corona‐mediated biological identity, microenvironment‐responsive activation, and biodistribution modeling.
Sheng-Bin Liu, Zhi Liu, Hai-Xing Shi et al.· MedComm· 0 citations
The potential of artificial intelligence in drug discovery and development, has been explored in this review, encircling several stages from identification of target to its clinical applications, followed by drug development approaches encompassing the future of artificial intelligence in the pharmaceutical sector.
Diptanu De, Sohini Chakraborty, Satarupa Banerjee· Frontiers in Oncology· 0 citations
Breast cancer remains a leading cause of cancer-related mortality worldwide, and its clinical management continues to be complicated by substantial tumor heterogeneity. Two technological forces are reshaping the therapeutic and diagnostic landscape of this disease: nanotechnology and artificial intelligence (AI). Nanom...
M. Omer· Biomedical & Pharmacolog...· 0 citations
The analysis suggests that AI will become an increasingly important component of pharmaceutical workflows; however, long-term impact will depend less on algorithmic advancement alone and more on effective integration with biological validation, experimental rigor, clinical evidence, and scalable translational infrastru...
Andrew Matelis· American Journal of Student...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.